Active immunization with Aβ has proved to be an efficient way to reduce brain amyloid load in APP transgenic mouse models of AD [8-10], but their first clinical trials needed to be discontinued due to development of fulminant meningo-encephalitis in a considerable number of patients [11]. This evidence concerns the gene APP and Alzheimer disease.